A scalable controlled-release device for transscleral drug delivery to the retina

Biomaterials

Volumn 32, Issue 7, 2011, Pages 1950-1956

  Kawashima, Takeaki ^a   Nagai, Nobuhiro ^b   Kaji, Hirokazu ^a,c   Kumasaka, Norihiro ^b   Onami, Hideyuki ^b   Ishikawa, Yumi ^b   Osumi, Noriko ^b   Nishizawa, Matsuhiko ^a,c   Abe, Toshiaki ^b  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Controlled release; Drug delivery system; Polyethylene glycol; Retinal neuroprotection; Transscleral delivery

Indexed keywords

CONTROLLED DRUG RELEASE; CONTROLLED RELEASE; DIMETHACRYLATES; DRUG FORMULATIONS; DRUG PERMEATION; DRUG RESERVOIR; DRUG-DELIVERY SYSTEMS; EYE TISSUES; HUMAN BRAIN; MICRO-PARTICLES; NEUROPROTECTION; RABBIT EYES; RELEASE RATE; RETINAL PIGMENT EPITHELIUM; SUSTAINED-RELEASE; TRANSSCLERAL DELIVERY;

ALDEHYDES; DRUG PRODUCTS; GLUCOSE; MEMBRANES; OPHTHALMOLOGY; PELLETIZING; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; POLYETHYLENES; THERMOPLASTICS;

CONTROLLED DRUG DELIVERY;

COLLAGEN; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; MACROGOL; RECOMBINANT BRAIN DERIVED NEUROTROPHIC FACTOR;

ANIMAL TISSUE; ARTICLE; ARTIFICIAL MEMBRANE; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE MEMBRANE; DRUG DELIVERY SYSTEM; DRUG PENETRATION; EXPERIMENTAL RABBIT; NONHUMAN; PARTICLE SIZE; PIGMENT EPITHELIUM; POLYMERIZATION; PRIORITY JOURNAL; RETINA; SCLERA; SUSTAINED DRUG RELEASE;

ANIMALS; BLOTTING, WESTERN; BRAIN-DERIVED NEUROTROPHIC FACTOR; COLLAGEN; DEXTRANS; DRUG DELIVERY SYSTEMS; FLUORESCEIN-5-ISOTHIOCYANATE; HUMANS; MICROSCOPY, ELECTRON, SCANNING; RABBITS; RETINA;

ORYCTOLAGUS CUNICULUS;

EID: 78650988630     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.11.006     Document Type: Article

References (33)

1. Hughes P.M., Olejnik O., Chang-Lin J.E., Wilson C.G. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev 2005, 57:2010-2032.
2. Geroski D.H., Edelhauser H.F. Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev 2001, 52:37-48.
3. Ranta V.P., Urtti A. Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling. Adv Drug Deliv Rev 2006, 58:1164-1181.
4. Ambati J., Adamis A.P. Transscleral drug delivery to the retina and choroid. Prog Retin Eye Res 2002, 21:145-151.
5. Olsen T.W., Edelhauser H.F., Lim J.I., Geroski D.H. Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci 1995, 36:1893-1903.
6. Myles M.E., Neumann D.M., Hill J.M. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv Drug Deliv Rev 2005, 57:2063-2079.
7. Kunou N., Ogura Y., Yasukawa T., Kimura H., Miyamoto H., Honda Y., et al. Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis. J Control Release 2000, 68:263-271.
8. McHugh A.J. The role of polymer membrane formation in sustained release drug delivery systems. J Control Release 2005, 109:211-221.
9. LaVail M.M., Unoki K., Yasumura D., Matthes M.T., Yancopoulos G.D., Steinberg R.H. Multiple growth factors, cytokines, and neurotrophins rescue photoreceptors from the damaging effects of constant light. Proc Natl Acad Sci U S A 1992, 89:11249-11253.
10. Di Polo A., Aigner L.J., Dunn R.J., Bray G.M., Aguayo A.J. Prolonged delivery of brain-derived neurotrophic factor by adenovirus-infected Muller cells temporarily rescues injured retinal ganglion cells. Proc Natl Acad Sci U S A 1998, 95:3978-3983.
11. Adamus G., Sugden B., Shiraga S., Timmers A.M., Hauswirth W.W. Anti-apoptotic effects of CNTF gene transfer on photoreceptor degeneration in experimental antibody-induced retinopathy. J Autoimmun 2003, 21:121-129.
12. Faktorovich E.G., Steinberg R.H., Yasumura D., Matthes M.T., LaVail M.M. Photoreceptor degeneration in inherited retinal dystrophy delayed by basic fibroblast growth factor. Nature 1990, 347:83-86.
13. Abe T., Yoshida M., Yoshioka Y., Wakusawa R., Tokita-Ishikawa Y., Seto H., et al. Iris pigment epithelial cell transplantation for degenerative retinal diseases. Prog Retin Eye Res 2007, 26:302-321.
14. Kalachandra S. Influence of fillers on the water sorption of composites. Dent Mater 1989, 5:283-288.
15. Hashimoto M., Kaji H., Nishizawa M. Selective capture of a specific cell type from mixed leucocytes in an electrode-integrated microfluidic device. Biosens Bioelectron 2009, 24:2892-2897.
16. Lin-Gibson S., Bencherif S., Cooper J.A., Wetzel S.J., Antonucci J.M., Vogel B.M., et al. Synthesis and characterization of PEG dimethacrylates and their hydrogels. Biomacromolecules 2004, 5:1280-1287.
17. Weber L.M., He J., Bradley B., Haskins K., Anseth K.S. PEG-based hydrogels as an in vitro encapsulation platform for testing controlled beta-cell microenvironments. Acta Biomater 2006, 2:1-8.
18. Nagai N., Kumasaka N., Kawashima T., Kaji H., Nishizawa M., Abe T. Preparation and characterization of collagen microspheres for sustained release of VEGF. J Mater Sci Mater Med 2010, 21:1891-1898.
19. Meier M.M., Kanis L.A., Soldi V. Characterization and drug-permeation profiles of microporous and dense cellulose acetate membranes: influence of plasticizer and pore forming agent. Int J Pharm 2004, 278:99-110.
20. Vogelaar L., Lammertink R.G., Barsema J.N., Nijdam W., Bolhuis-Versteeg L.A., van Rijn C.J., et al. Phase separation micromolding: a new generic approach for microstructuring various materials. Small 2005, 1:645-655.
21. Grinberg O., Binderman I., Bahar H., Zilberman M. Highly porous bioresorbable scaffolds with controlled release of bioactive agents for tissue-regeneration applications. Acta Biomater 2010, 6:1278-1287.
22. Yoon J.J., Park T.G. Degradation behaviors of biodegradable macroporous scaffolds prepared by gas foaming of effervescent salts. J Biomed Mater Res 2001, 55:401-408.
23. Brandl F., Kastner F., Gschwind R.M., Blunk T., Tessmar J., Gopferich A. Hydrogel-based drug delivery systems: comparison of drug diffusivity and release kinetics. J Control Release 2010, 142:221-228.
24. Klocker N., Kermer P., Weishaupt J.H., Labes M., Ankerhold R., Bahr M. Brain-derived neurotrophic factor-mediated neuroprotection of adult rat retinal ganglion cells in vivo does not exclusively depend on phosphatidyl-inositol-3'-kinase/protein kinase B signaling. J Neurosci 2000, 20:6962-6967.
25. Pernet V., Di Polo A. Synergistic action of brain-derived neurotrophic factor and lens injury promotes retinal ganglion cell survival, but leads to optic nerve dystrophy in vivo. Brain 2006, 129:1014-1026.
26. Mansour-Robaey S., Clarke D.B., Wang Y.C., Bray G.M., Aguayo A.J. Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and regrowth of axotomized retinal ganglion cells. Proc Natl Acad Sci U S A 1994, 91:1632-1636.
27. Martin K.R., Quigley H.A., Zack D.J., Levkovitch-Verbin H., Kielczewski J., Valenta D., et al. Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. Invest Ophthalmol Vis Sci 2003, 44:4357-4365.
28. Harper M.M., Adamson L., Blits B., Bunge M.B., Grozdanic S.D., Sakaguchi D.S. Brain-derived neurotrophic factor released from engineered mesenchymal stem cells attenuates glutamate- and hydrogen peroxide-mediated death of staurosporine-differentiated RGC-5 cells. Exp Eye Res 2009, 89:538-548.
29. Robinson M.R., Lee S.S., Kim H., Kim S., Lutz R.J., Galban C., et al. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res 2006, 82:479-487.
30. Demetriades A.M., Deering T., Liu H., Lu L., Gehlbach P., Packer J.D., et al. Trans-scleral delivery of antiangiogenic proteins. J Ocul Pharmacol Ther 2008, 24:70-79.
31. Wong T.Y., Liew G., Mitchell P. Clinical update: new treatments for age-related macular degeneration. Lancet 2007, 370:204-206.
32. Sanborn G.E., Anand R., Torti R.E., Nightingale S.D., Cal S.X., Yates B., et al. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device. Arch Ophthalmol 1992, 110:188-195.
33. Jaffe G.J., Martin D., Callanan D., Pearson P.A., Levy B., Comstock T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006, 113:1020-1027.